Openbookopenbook
Equity
Bayer AG NA(0P6S)
EUR --+0.00%
Reward48Moderate
Risk29Low
📊50%Data
Thin -8% profit margin
0P6S
+0.0 · +0.00%
EUR · LSE
Bayer AG NA |
Earnings Deterioration
Market Cap:51.70Bn
ℹ️
Reward Rating
48
Moderate
Bottom 25% (model universe)
50% data coverage
ℹ️
Risk Rating
29
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0P6S to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Bayer AG NA?

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.

0P6S · Verdict

Moderate reward · low risk

0P6S stands out on cash flow and balance sheet, but watch the profitability signal.

Based on 75% data coverage

0P6S · Verdict

What’s working & what to watch

Strengths 2

  • Cash flow80/100

    Top decile vs peers

  • Balance sheet75/100

    Current ratio 1.08

Watchouts 1

  • Profitability33/100

    -12% return on equity

Model-based scoring. For information only — not financial advice.

What is Bayer AG NA?

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The company is listed on the LSE in UK, with a market capitalisation of 51.70B.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (48)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap51.70B
P/E RatioN/A
Dividend Yield0.19%
52 Week High49.6386
52 Week Low21.9774
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees87,280
IndustryN/A
ExchangeLSE
Beta0.888
CurrencyEUR
Websitewww.bayer.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.